SV Health Investors
SV Health Investors, formerly SV Life Sciences, is a leading healthcare and life sciences venture capital and growth equity firm.Our goal is to transform healthcare – one investment at a time – by supporting the entrepreneurs who create and build breakthrough companies and treatments
With over $2.9 billion in capital commitments raised across seven private venture capital funds and one publicly listed fund, a 25-year track record in the US and Europe with offices in Boston and London, SV Health Investors drives game-changing innovation.
Johnson & Johnson Innovation – JJDC
Johnson & Johnson Innovation – JJDC is the venture capital subsidiary of Johnson & Johnson, and is comprised of experts and leaders in the health care and technology venture communities who identify early market indicators, healthcare trends, and strategic investment opportunities. They invest in companies with technologies that they believe have the potential to make significant impact on patient health.
F-Prime Capital is the new, unified name for the venture capital funds of FMR LLC, the parent company of Fidelity Investments, and continue its 40-year history as an active global investor in life sciences, healthcare and technology. Over the past 15 years, the F-Prime Capital teams have invested in more than 89 companies in five countries across five funds. The teams have focused on innovative early stage companies addressing significant needs in the technology and life sciences sectors.
IP Group was set up with a mission to evolve great ideas, mainly from our partner universities, into world-changing businesses. We achieve this by systematically helping to create, build and support outstanding intellectual property-based companies.
The Group pioneered the concept of the long-term partnership model with UK universities and has spent many years honing a unique approach to building businesses and providing support along the journey from “cradle to maturity”. We have replicated this approach with a select group of US research institutions and, in 2017, the Group announced it was expanding into Australasia.
Longwood Fund is a leading healthcare venture capital firm that founds, manages, and builds healthcare companies. Longwood’s mission is to identify technologies and to found companies that will advance new therapeutics that not only make a difference in the lives of patients worldwide, but also create significant value for investors. This is achieved by leveraging the management team’s history of successful healthcare company formation and operational leadership.
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. We have a team of investment professionals, located in the US and UK. As a Team, our experience spans basic science, industry and the market. We take an active role in our portfolio companies and work with management teams and our fellow venture investors to create significant value. Celebrating its 30th anniversary in 2015, SR One has invested $1B in more than 170 companies, and its current portfolio includes 40 private and public companies. Our expanded remit also focuses on maximizing the value of GSK technological innovation to establish new businesses and revenue opportunities across a range of industries.
Asahi Kasei Pharma Ventures was established in 2018 and is focused on investing in innovative global companies in areas of strategic importance to Asahi Kasei Pharma with a special focus on rare diseases. Our primary mission is to participate and help develop breakthrough medical innovations and to create new long-term business opportunities for Asahi Kasei. Our US office is based in the Boston, MA area